These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 9750518)

  • 1. [Surgical or medical castration with LH-RH analogue for prostatic cancer].
    Kameyama S; Yamazaki S; Kitamura T
    Nihon Rinsho; 1998 Aug; 56(8):2114-8. PubMed ID: 9750518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence that prostate gonadotropin-releasing hormone receptors mediate an anti-tumourigenic response to analogue therapy in hormone refractory prostate cancer.
    Gnanapragasam VJ; Darby S; Khan MM; Lock WG; Robson CN; Leung HY
    J Pathol; 2005 Jun; 206(2):205-13. PubMed ID: 15818594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Assessment of the quality of life (QOL) of prostatic cancer patients under LH-RH analogue treatment].
    Ueda S; Nishi K; Yoshida M
    Nihon Rinsho; 1998 Aug; 56(8):2119-23. PubMed ID: 9750519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Total androgen blockade--concept, theory, method and clinical application].
    Ozono S; Hirao Y
    Nihon Rinsho; 1998 Aug; 56(8):2129-34. PubMed ID: 9750521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Management of a hormone dependent cancer with endocrine therapy--prostate cancer].
    Tsukamoto S; Akaza H
    Gan To Kagaku Ryoho; 2001 Jul; 28(7):917-26. PubMed ID: 11478140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hormonal therapy for prostatic cancer--state of the art].
    Miyakita H
    Nihon Rinsho; 2005 Feb; 63(2):305-8. PubMed ID: 15714983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent developments in endocrine treatment of prostate cancer.
    Vogelzang NJ; Kennealey GT
    Cancer; 1992 Aug; 70(4 Suppl):966-76. PubMed ID: 1386283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controversies in the management of advanced prostate cancer.
    Tyrrell CJ
    Br J Cancer; 1999 Jan; 79(1):146-55. PubMed ID: 10408706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Recent advance in luteinizing hormone-releasing hormone analogue therapy in management of prostate cancer].
    Kawai K; Akaza H
    Nihon Rinsho; 1998 Aug; 56(8):2108-13. PubMed ID: 9750517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endocrine therapy for prostate cancer.
    Sagalowsky AI
    Spec Top Endocrinol Metab; 1985; 7():101-29. PubMed ID: 3914094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer.
    Scherr DS; Pitts WR
    J Urol; 2003 Nov; 170(5):1703-8. PubMed ID: 14532759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endocrine treatment of prostate cancer.
    Tammela T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The fate of the medically castrated testis: expectation versus reality.
    Issa MM; Krishnan A; Bouet R; Young MR; Hood N; Petros JA
    J Urol; 2004 Sep; 172(3):1042-4. PubMed ID: 15311033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
    Kobayashi T; Nishizawa K; Mitsumori K
    Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Theoretical considerations and initial clinical results of intermittent hormone treatment of patients with advanced prostatic carcinoma].
    Bruchovsky N; Goldenberg SL; Rennie PS; Gleave M
    Urologe A; 1995 Sep; 34(5):389-92. PubMed ID: 7483155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen deprivation falls as orchiectomy rates rise after changes in reimbursement in the U.S. Medicare population.
    Weight CJ; Klein EA; Jones JS
    Cancer; 2008 May; 112(10):2195-201. PubMed ID: 18393326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Can serum testosterone level measurement extend the intervals of administration of a long-acting LHRH agonist ?].
    Kawamura K
    Hinyokika Kiyo; 2010 Jun; 56(6):301-4. PubMed ID: 20610920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Keyrole of endocrinology in the victory against prostate cancer].
    Labrie F
    Bull Cancer; 2006 Sep; 93(9):949-58. PubMed ID: 16980238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer.
    Labrie F; Dupont A; Giguère M; Borsanyi JP; Lacourciere Y; Bélanger A; Lachance R; Emond J; Monfette G
    Prog Clin Biol Res; 1988; 260():41-62. PubMed ID: 3283766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.